Cyprium Therapeutics, a Fortress Biotech Subsidiary Company, Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease, to Sentynl Therapeutics, a Wholly-owned Subsidiary of Zydus Lifesciences Ltd. Dec 06, 2023
Journey Medical Corporation Announces Successful Completion of Pre-NDA Meeting with the FDA for DFD-29 to Treat Rosacea Dec 06, 2023
Checkpoint Therapeutics Strengthens Intellectual Property Protection for Cosibelimab with New U.S. Patent Issuance Dec 05, 2023
Fortress Biotech Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights Nov 14, 2023
Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights Nov 14, 2023
Checkpoint Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights Nov 13, 2023
Avenue Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights Nov 13, 2023
